Overcoming FVIII Inhibitors With Efanesoctocog Alfa – JTH
Journal of Thrombosis and Haemostasis (JTH) shared a post on LinkedIn about a recent article by Aqsa Ashraf et. al, adding:
“Successful immune tolerance induction using efanesoctocog alfa in severe hemophilia A: a case series
Two patients with severe hemophilia A and complex inhibitor histories underwent immune tolerance induction with efanesoctocog alfa at 100 U/kg three times weekly.
Inhibitor titers became undetectable within six weeks and three months, with FVIII recovery above 90%.
Once-weekly prophylaxis maintained troughs of 4-6% and bleed-free outcomes, allowing emicizumab discontinuation.”
Title: Successful immune tolerance induction using efanesoctocog alfa in severe hemophilia A: a case series
Authors: Aqsa Ashraf, Rebekah Kuhlman, Osman Khan, Sanober Nusrat
Stay updated with Hemostasis Today.
-
Oct 4, 2026, 13:04World Federation of Hemophilia Invites Global Community to GPAS 2026
-
Oct 4, 2026, 12:57Tooth Extraction in Patients with Haemophilia – RPTH Journal
-
Oct 4, 2026, 12:36Maia Meier: Advancing Hemophilia Care in Nepal – Project Elevate Her Visits Civil Service Hospital
-
Oct 4, 2026, 12:30Shailaja Kota Amplifies World Inherited Blood Disorders Month and Global Action Network’s Call to Action
-
Oct 4, 2026, 12:21Davide Pallucci: How Altered Platelet Metabolism Can Drive Changes in their Reactivity in Human and Mouse MASLD
-
Oct 4, 2026, 11:02Stimuli-Induced Remodeling of the Platelet Lipidome in Pulmonary Embolism – ESC
-
Oct 4, 2026, 10:45Join the Bleeding Disorders Advocacy Network! – HFA
-
Oct 4, 2026, 06:12David McIntosh: 900 Plasma Donations One Patient One Lifeline
-
Oct 4, 2026, 06:00Aadil Sheikh: Menopausal Hormone Therapy and Thrombosis Rethinking Route Dose and Risk